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Summary
Alzheimer′s Disease (AD) is the most common neurodegenerative disorder in elderly people. It is 
becoming an ever larger problem due to prolonged life-expectancies in developed countries. One of the 
central pathological hallmarks of the disease are deposits of aggregated amyloid β (Aβ), a peptide 
proteolytically derived from the amyloid precursor protein (APP). Although the contribution of APP to 
the pathology of AD has been at the center of most AD research for about two decades, the 
physiological role of this membrane protein still remains elusive. APP belongs to a conserved gene 
family including the amyloid precursor-like proteins 1 and 2 (APLP1 and APLP2). While mice lacking 
individual genes do not display any overt phenotype, double null mutations for app and aplp2 result in 
early postnatal lethality, at the time when neuronal activity begins to be essential. These findings 
suggest functional redundancy of APP and APLP2, which is further supported by their similar pattern of 
expression. In order to address the role of these genes during neuronal differentiation, we made use of a 
newly established method allowing the generation of uniform populations of neurons starting with 
cultured mouse embryonic stem (ES) cells. This protocol leads to the generation of an essentially pure 
population of neural progenitors defined as Pax6-positive radial glial cells. As known from recent cell 
lineage analyses in vivo, these progenitors give rise to essentially all pyramidal, glutamatergic neurons 
in the cerebral cortex and in the hippocampus. In this work, we made use of ES cells lacking both app
and aplp2 and compared some of the biochemical properties of neurons derived from such cells with 
those obtained from wild-type ES cells. In the absence of app and aplp2, we detected a marked 
reduction in the expression of one of the vesicular transporters for glutamate, VGLUT2. In line with 
this, we found that the reduction in transporter levels is functionally significant, as less glutamate was 
released from these neurons following depolarizing stimuli. With regard to possible mechanisms linking 
the transcription of vglut2 and APP, we blocked γ-secretase activity in wild-type neurons and observed 
that inhibition of the generation of a soluble intracellular domain of APP (AICD) leads to a decrease in 
the transcription of vglut2.
The present work thus suggests a link between APP and the development of glutamatergic synapses.  
This may provide an explanation for the early postnatal lethality of animals lacking both app and aplp2.
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Dysfunction of APP processing might also provide a mechanistic link explaining some of the synaptic 
alterations thought to occur in AD.
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1.1 Alzheimer’s Disease (AD)
Alzheimer’s disease is a neurodegenerative disoarder leading to cognitive, memory and behavioral 
impairments. It is the most common form of dementia in people over 65 years of age and it will become 
an increasing health problem due to extended life-expectancies in developed countries. No cure or 
preventative therapy is available yet and the definitive diagnosis is still based on postmortem 
histopathological examinations of the brains of patients. Two types of aggregates characterize the 
disease: extracellular deposits of amyloid β (Aβ) peptide in senile plaques and intraneuronal 
neurofibrillary tangles formed by hyperphosphorylated tau (review de Strooper et al., 2000; review
Tanzi et al., 2005). 
While the vast majority of AD cases are sporadic, about 5% are caused by mutations (familiar 
Alzheimer′s Disease, FAD). Genetic studies on these inherited forms allowed considerable progress to 
be made with regard to possible mechanisms underlying the disease. Indeed, several mutations have 
been found in a gene encoding the amyloid precursor protein (APP). APP is a transmembrane protein 
known to be processed by two different cleavage pathways in vivo (Fig.1). In the predominant “non-
amyloidogenic pathway”, APP is cleaved by α-secretase within the Aβ domain. A soluble extracellular
fragment (sAPPα) and a C-terminal fragment (C83) are produced. The latter can be further cleaved
intramembranously by γ-secretase to produce a small peptide, P3 and the APP intracellular domain
(AICD). In the “amyloidogenic pathway” APP is cleaved by β-secretase (BACE-1), leading to the 
generation of a soluble extracellular fragment (sAPPβ) and of a C-terminal fragment (C99). C99 can be 
further processed by γ-secretase to release the AICD and Aβ. Both cleavage pathways take place under 
physiological conditions and therefore suggest that all fragments of APP, including Aβ, may be part of 
hitherto unrecognized, normal processes.
1
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Figure 1: Cleavage schema of APP
APP is first cleaved by either α- or β-secretase releasing a soluble extracellular fragment (sAPPα or sAPPβ). The 
remaining C-terminal fragments, C83 or C99, are further cleaved by γ-secretase resulting in the generation of 
either a small extracellular fragment P3 (after C83 cleavage) or Aβ (after C99 cleavage). In addition the APP 
intracellular domain (AICD) is released. (TMD = transmembrane domain)
The next breakthrough in the characterization of the mechanisms underlying AD came with the 
discovery of mutations in genes encoding for presenilin1 (PS1) and 2 (PS2), two related membrane 
proteins that have recently been identified as being part of the multiprotein proteolytic complex γ-
secretase. The identification of PS1 and PS2 was a major finding with implications extending well 
beyond the field of AD. Indeed, both presenilins are also involved in the processing of other 
transmembrane proteins, including Notch in particular, the cleavage of which had remained a mystery 
before the identification of PS1 and PS2 (review Selkoe et al., 2002; review de Strooper, 2003).
An increase in the production of Aβ is common to most of the hereditary forms of AD. This is also 
illustrated by patients affected by Down syndrome (Trisomy 21). After the age of 40, the majority of 
them develop AD pathology with neuritic plaques and tangle formation. As the APP gene is localized 
on chromosome 21, Down syndrome patients harbor three copies of the APP gene and it seems that the 
increase in copy number may be sufficient to induce AD pathology. 
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Interestingly, mutations in the tau gene, encoding for the other protein found to be altered in the brain 
of AD patients, are not associated with Alzheimer′s disease. Mutated tau can lead to frontotemporal
dementia with parkinsonism (FTDP-17), another severe form of dementia which is characterized by 
widespread deposition of tangles but absence of amyloid plaques. Therefore FTDP-17 is not classified 
as AD (review de Strooper et al., 2000).
Taken together, the human genetics of AD points to APP and its processing being directly implicated in 
the pathology of the disease. While mutations in the corresponding genes only account for a relatively 
small percentage of AD cases, it is of interest that the pathological lesions in sporadic forms of AD are 
similar to those found in the hereditary forms. Therefore it can be assumed that changes in the 
processing of APP also play a role in the pathogenesis of the much more frequent, non-familial form. 
However, neither the physiological function of the fragments (related or not related to Aβ) generated by 
the proteolysis of APP, nor the physiological function of APP is known at this point. This latter question 
was the basis of the present work which we approached using a newly developed cell culture system 
allowing the generation of neurons from embryonic stem cells lacking APP and its relative APLP2. 
1.2 APP gene family
The amyloid precursor protein belongs to a gene family that comprises 3 members in mammals: 
amyloid precursor protein (APP), amyloid precursor-like protein 1 (APLP1) and amyloid precursor-like 
protein 2 (APLP2). Homologues have also been found in the fruit fly Drosophila melanogaster, 
amyloid precursor protein like protein (APPL), and in the worm Caenorhabditis elegans, amyloid
protein-like protein 1 (apl-1; review de Strooper et al., 2000).
All three proteins are type I transmembrane proteins with a large extracellular (~624-700 amino acids), 
a transmembrane (~25 amino acids) and a short intracellular (~46 amino acids) domain. They are 
clearly related in sequence, with a slightly closer similarity between APP and APLP2 (APLP1 versus 
APP: 42%; APLP2 versus APP: 52% and APLP1 versus APLP2: 43% amino acid identities in human; 
Wasco et al., 1992; Wasco et al., 1993). The main difference is the lack of the Aβ sequence in the two 
APP like proteins. Remarkably, no mutations associated with AD have been found in the aplp1 and 
aplp2 genes so far, a finding that further supports the view that Aβ is linked to AD, not least because 
both
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both, APLP1 and APLP2, are proteolytically processed in the same manner as APP (Lo et al., 1995; 
Paliga et al., 1997; Li et al., 2004).
With regard to the expression patterns of the three genes, APP and APLP2 mRNAs are found in largely 
overlapping patterns during embryogenesis and in adult tissue. They are expressed in the central and 
peripheral nervous system, as well as in most organs (Slunt et al., 1994). In the adult brain, the 
transcripts are found not only in the same brain regions, but also at similar levels. For example high 
levels are found in the temporal association cortex and lower levels in the hippocampus (Wasco et al., 
1993). APLP1 is only found in the developing and adult central and peripheral nervous system, but not 
in non-neuronal tissue (Lorent et al., 1995).
The physiological function of APP and its homologues still remains unclear. A large body of in vitro
experiments suggests a contribution of APP to multiple cellular processes including neurite outgrowth 
(Zheng et al., 1995; Sabo et al., 2003), neuronal survival (Perez et al., 1997), cell-cell adhesion 
(Yamazaki et al., 1997; Coulson et al., 2000), axonal transport (Kamal et al., 2000; 2001), cell 
proliferation (Ohsawa et al., 1999; Caille et al., 2004), synaptogenesis (Schubert et al., 1991; Moya et 
al., 1994; Morimoto et al., 1998; Kirazov et al., 2001; Kamenetz et al., 2003; Wang et al., 2005; Yang 
et al., 2005) and transcriptional regulation (Cao et al., 2001). Some of these functions have also been 
described for APLP1 and APLP2, such as neurite outgrowth (Thinakaran et al., 1995), synaptogenesis
(Kim et al., 1995; Wang et al., 2005; Yang et al., 2005), cell proliferation (Caille et al., 2004) and 
transcriptional regulation (Scheinfeld et al., 2002). 
To elucidate the physiological role of the app and app-related genes, mice deficient in either APP, 
APLP1 or APLP2 have been generated (Müller et al., 1994; Zheng et al., 1995; Li et al., 1996; von 
Koch et al., 1997; Heber et al., 2000). All single mutants are viable and fertile with only subtle 
neurological deficits in the case of APP deficiency, suggesting redundancy of function among the APP 
gene family members. This view is supported by the phenotypes of combined null mutants. The lack of 
APP and APLP2 or APLP1 and APLP2 results in early postnatal lethality (P0) without
histopathological abnormalities in any of the organs examined including the brain. By contrast, the lack 
of APP and APLP1 results in viable mice without any detectable phenotype (von Koch et al., 1997; 
Heber et al., 2000).
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Why on the other hand the combination of null mutations in the aplp1 and aplp2 genes should be lethal 
if APP and APLP2 exert the same function remains unclear at this point and is not easy to explain.
1.3 APP gene family members: possible synaptic functions
The expression of APP and APLP2 is developmentally regulated and a strong increase in expression 
occurs at the time of synaptogenesis (Moya et al., 1994; Kirazov et al., 2001). These observations led to 
the hypothesis that both proteins may have a role in synapse formation and maturation. In addition, APP 
and APLP2 are transported to presynaptic sites by kinesin-I dependent fast anterograde axonal transport 
(Koo et al., 1990; Schubert et al., 1991). APP itself is thought to be involved in the transport mechanism 
by serving as a membrane cargo receptor for kinesin-I, linking this protein to a subset of other axonally
transported vesicles, possibly including those containing molecules required for proper synaptic 
function such as neurotransmitter transporters (Kamal et al., 2000 and 2001).
Observations made with APP antibodies applied to primary hippocampal cultures further suggest a role 
of APP in synapse maturation and/or function (Morimoto et al., 1998). A decrease of spontaneous 
synchronous neuronal oscillations could be observed after antibody treatment of the neurons. These 
oscillations of [Ca2+]i result from the spontaneous activity of neurons forming synapses, and the number 
of synchronized neurons was found to correlate with the number of synapses formed. Blocking APP 
with an antibody might therefore result in the inhibition of the formation of functional synapses.
Very recently, the notion that APP and APLP2 may be somehow involved in synaptic function received 
further support by two publications (Wang et al., 2005; Yang et al., 2005) indicating defects in synaptic 
structure and synaptic transmission in the neuromuscular junction and submandibular ganglia of mice 
lacking both genes (see Discussion).
1.4 Aim of the thesis
Given our lack of understanding of the role of APP and APLP2, as well as the early postnatal death of 
the double mutants, it would be desirable to investigate this question using cultured cells. Neuronal 
cultu
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cultures have been established from the embryonic brains of double knock-out animals, but they did not 
help to bring further insight into the role of APP and APLP2 (Heber et al., 2000). Both the inherent 
heterogeneity of such cultures, as well as the limited quantities of cells contribute to make biochemical 
assays and screens difficult.
In the present work, we took advantage of a novel cell culture protocol based on the use of mouse 
embryonic stem (ES) cells (Bibel et al., 2004). Our laboratory has recently shown that homogeneous 
populations of glutamatergic neurons can be obtained from wild-type ES cells. As ES cells can be 
generated in unlimited quantities, they represent a potentially attractive model to study the 
consequences of selective gene deletion in differentiated neurons in vitro. ES cells were derived from 
blastocysts of app/aplp2 double mutant animals and their differentiation into neurons was compared 
with that of wild-type ES cells using biochemical, molecular biological and functional methods.
Introduction
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Materials and Methods
2.1 Differentiation of embryonic stem (ES) cells
2.1.1 Feeder preparation
Feeder medium
2
Invitrogen #21969-035to final volumeDMEM
(+ high glucose
+ sodium pyruvate
- glutamine)
Invitrogen #25030-0240.8 mMglutamine (200 mM)
Invitrogen, personal 
reservation, heat inactivated 30 
min at 55°C
10%FCS
supplierconcentration
Embryos day 13.5-14.5 after gestation were decapitated and all inner organs, spinal cord and extremities 
were removed. The remaining tissue was cut into small pieces and incubated in 1 ml trypsin/0.5% 
EDTA (Invitrogen #25300-054) for 30 min at 37°C.
10 ml feeder medium were added for trypsin inactivation and after 5 min incubation the supernatant was 
transferred into a fresh tube. 10 ml feeder medium were added again to the remaining tissue-pellet and 
incubated for 5 min before the supernatant was collected. The procedure was repeated three times in 
total. The supernatant was filtered through a cell strainer (BD Falcon™ #352360; 100 μm pore size) and 
centrifuged for 5 min at 1000 rpm. The pellet was resuspended in feeder medium and plated on 150 cm2
culture flasks (BD Falcon™ #355000), one embryo per two plates. The feeders were expanded once 
before aliquots were frozen.
Materials and Methods
2.1.2 Embryonic stem cell cultivation 
ES medium
Invitrogen #21969-035to final volumeDMEM
Sigma #M75220.001%β-mercaptoethanol
Invitrogen #25030-0240.8 mMglutamine (200 mM)
Chemicon, ESG1107, 107
Units/ml
103 Units/mlLeukemia inhibitory factor 
(LIF)
Invitrogen #11140-0351xnon-essential amino acids
(100x)
Invitrogen, personal
reservation, heat inactivated 30 
min at 55°C
15%FCS
supplierconcentration
Feeder cells were plated on 6 cm culture plates precoated with 0.2% gelatine (precoating of plates for at 
least 10 min; Sigma #G-1890) and cultivated in feeder medium. After grown to confluency feeder cells 
were inactivated by incubation in 1 mg/ml Mitomycin C (Sigma #M0503) for 2 hours. After washing 
three times with PBS (Invitrogen #3094370) ES medium was added. ES cells were plated on the feeder 
cell layer and splitted every other day to allow colonies to grow separately. Stem cells were splitted by 
washing once with PBS and incubation in 2.5 – 5ml trypsin/EDTA at 37°C until the cells detached from 
the plate. Cells were triturated in trypsin solution to obtain a single cell suspension and trypsin was 
finally inactivated by adding 5-7 ml of ES medium. Cells were centrifuged for 5 min at 1000 rpm and 
the pellet was resuspended in 5 ml ES medium. Cells were plated on freshly inactivated feeder cells. 
After three to four passages stem cells were plated on gelatine-coated 10 cm plates (Corning #430167) 
without feeder cells. Stem cells were splitted according to density and morphology every second day 
and the medium was replaced every other day. High proliferation was necessary for successful 
differentiation as well was it important that the cells were in a phase of rapid growth and formed a flat 
monolayer. Stem cells were either used for embryoid body formation immediately or frozen for later 
use. 
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Freezing of ES cells
For freezing, cells were trypsinized and centrifuged as for splitting. The pellet was resuspended in ES 
medium containing 10% DMSO (Dimethyl Sulfoxide; Sigma #D-4540) and the cell suspension was 
transferred into cryo tubes that were frozen in cryo boxes at -80°C. After 2-7 days the cryo vials were 
transferred to liquid nitrogen. 
2.1.3 Embryoid body (EB) formation
EB medium
Invitrogen #21969-035to final volumeDMEM
Sigma #M75220.001%β-mercaptoethanol
Invitrogen #25030-0240.8 mMglutamine (200 mM)
Invitrogen #11140-0351xnon-essential amino acids
(100x)
Invitrogen, personal
reservation, heat inactivated 30 
min at 55°C
10%FCS
supplierconcentration
For EB formation stem cells were trypsinized according to the splitting protocol and resuspended in EB 
medium after centrifugation. Cells were counted either in a Neubauer counting chamber or with Casy® -
1 (Schärfe System GmbH, Reutlingen). The number of cells taken for EB formation was set 
individually for every ES cell line and was in the range of 1.5x106 to 4x106 ES cells. Cells were plated 
on bacterial dishes (Greiner bio-one #664160) in 15 ml EB medium.
The non-adhesive substrate of the bacterial dishes prevents attachment of the ES cells and free-floating 
three-dimensional structures, so-called embryoid bodies (EBs), are formed. EBs are kept in culture for 8 
days in total. Every other day the medium was changed by putting the cell solution into a 50 ml falcon 
tube, letting the aggregates settle down for 4-5 min, removing the supernatant and resuspending EBs in 
fresh medium. After 4 and 6 days in culture, 5 μM retinoic acid (Sigma #R2625) was added to initiate 
neuronal differentiation. 
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2.1.4 Trypsinization of EBs
Coating of culture plates
0.5 mg/ml poly-DL-ornithine hydrobromide (Sigma #P8638) was dissolved in boric buffer (boric acid; 
Riedel-de Haën® #31146; pH8.4) and filtered. The solution was diluted 1:5 in aqua ad inject (Aichele
Medico AG #530103) and culture plates (Nunc #150288) were coated in the incubator over night. After 
washing three times with aqua inject, laminin (Roche #11243217001) was added in a concentration of 
0.5 μg/cm2 in PBS for at least 2 hours.
N2 medium
Invitrogen #21969-035
Invitrogen #21765-029
mixed 1:1 to final 
volume
DMEM & F12
Sigma #A-941850 μg/ml10 mg/mlBSA
Sigma #S-526130 nM300 μMSodium Selenite
Sigma #P-578016 μg/ml160 mg/mlPutrescine
Sigma #P-87836 ng/ml20 μMProgesterone
Sigma #T-114750 μg/ml2 mg/mlApo-Transferrin
Sigma #I-663425 μg/ml5 mg/mlInsulin
supplierfinal concentrationstock solution
Complete medium
Medium was prepared according to Brewer et al. (1989) with the following chemicals omitted from the 
original protocol: glutamate, HEPES, corticosterone, lipoic acid, tri-iodothyronine.
Sigma #B-45020.1 μg/ml0.1 mg/mlBiotin
Sigma #A-76272 μg/ml2 mg/mlL-Alanin
supplierfinal solutionstock solutionaqueous solutions
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Sigma #T-32511 μg/ml100 mg/mlTocopherol
Sigma #Z-47500.194 μg/ml0.194 mg/mlZinc sulfate
Sigma #V-28760.34 μg/ml0.34 mg/mlVitamine B12
Sigma #S-13820.016 μg/ml0.016 mg/mlSodium-Selenite
Sigma #P-750516.1 μg/ml16.1 mg/mlPutrescine
Sigma #P-03807.76 μg/ml7.76 mg/mlL-Proline
Sigma #G-062515 μg/ml15 mg/mlD+ Galactose
Sigma #E-95081 μg/ml1 mg/mlEthanolamine
Sigma #C-02832 μg/ml2 mg/mlL-Carnitine
Sigma #C-4016 μg/ml16 mg/mlCatalase
Sigma #G-60131 μg/ml1 mg/mlGlutathione
Sigma #S-25152.5 μg/ml2.5 mg/mlSOD
ethanolic solutions
Sigma #L-13761 μg/ml100 mg/mlLinoleic acid
Sigma #L-23761 μg/ml100 mg/mlLinolenic acid
Sigma #P-87836.3 ng/ml0.63 mg/mlProgesterone
Sigma #R-7632100 ng/ml10 mg/mlall-trans-Retinol
Sigma #T-30011 μg/ml100 mg/mlTocopherolacetate
Sigma #R-7882100 ng/ml10 mg/mlRetinylacetate
supplierfinal solutionstock solutionaqueous solutions
Stock solutions of each ingredient were stored at -20°C and used within 6 month.
For 400 ml complete medium, 1 g BSA (Sigma #A-9418), 2 mg transferrin (Sigma #T-1147) and 1.6 
mg insulin (Sigma #I-6643) are dissolved in 30 ml DMEM and the remaining components are added, 
starting with the ethanolic solutions to dispose the foam. DMEM is added to final volume and medium 
is filtered and stored at 4°C for several weeks. Glutamine is added freshly before using the medium.
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Dissociation procedure
EBs were collected in 50 ml falcon tubes and washed twice with PBS. 500 μl freshly prepared 
trypsin/EDTA solution (0.05% trypsin in 0.04% EDTA/PBS; trypsin TPCK treated from bovine 
pancreas; Sigma #T-8802) was added to the EB pellet and incubated for 3 min at 37°C in the waterbath. 
The tube was gently shaken a few times. 10 ml EB medium were added to inactivate trypsin and EBs
were dissociated by pipetting carefully up and down 5 to 6 times. Cell suspension was centrifuged for 5 
min at 1000 rpm, the pellet was resuspended in 5 ml N2 medium and the whole suspension was filtered 
through a cell strainer (BD Falcon™ #352340; 40 μm pore size) to remove DNA and debris. Cells were 
counted and plated in a density between 4 and 5.5x106 cells on PORN/Laminin-coated 6 cm plates and 
between 0.7x106 and 1x106 cells on PORN/laminin-coated 12 well plates. N2 medium was replaced 
after 2 and 24 hours. After 48 hours the medium was exchanged to complete medium. Neurons were 
kept in complete medium for up to 3 weeks and medium was partially replaced during this time 
according to amount of debris. 
After dissociation of EBs cells can also be frozen for later use. For this purpose cells were resuspended
after centrifugation in EB medium with 10% DMSO (further processing see “freezing of ES cells”).
2.2 Immunostainings
Glass cover slips (Assistant, microscopical cover glasses, #1001/18) were prepared by incubating them 
in 65% nitric acid (Riedel-de Haën® #32213) for 1-2 d. After rinsing them with H2O for several hours 
they were floated in ethanol, air-dried and sterilized under UV light. Neurons grown on 
PORN/Laminin-coated cover slips were washed once with PBS and fixed with 4% paraformaldehyde
(PFA, prewarmed to 37°C; Merck #1.04005.1000) for 10 min, washed three times with PBS and either 
kept in PBS at 4°C until further processing or used immediately for immunostainings.
Immunostainings were performed by blocking the cells for 1 h at room temperature (RT) in blocking 
buffer (10% normal goat serum (Sigma #G-9023), 0.03% Carrageenan (Sigma #C-1138) and 0.3% 
Triton®X-100 (Fluka #93426)). Primary antibody was added in 2% NGS, 0.03% Carrageenan and 
0.3%Triton at 4°C over night. After washing three times with PBS the secondary antibody was added in
the same buffer for 1 hour at RT. DAPI (4′,6′-diamidino-2-phenylindole; 1:10000; AppliChem #28718-
90-3) was added following the secondary antibody treatment, for 3 min. Cover slips were washed three 
times with PBS before mounting in Aqua Poly Mount (Polyscience Incorporated #18606) on an object 
slide. Immunostained cover slips were stored in the dark at 4°C (for details about antibodies used see 
Table I).
2.3 Glutamate Release Assay
HANKs buffer
Materials and Methods
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Sigma #A-94180.25 %BSA
Sigma #H-614725 mMHEPES
Sigma #G-540010 mMGlucose
Sigma #Z-01521 μMZnCl2
Sigma #M-26701.2 mMMgCl2
Sigma #C-50801 mMCaCl2
Fluka #715001.2 mMNaH2PO4x2H2O
Fluka #601325 mMKCl
Fluka #71381125 mMNaCl
supplierconcentration
Glutamate release assay was performed as described in Griesbeck et al., 1999, with slight 
modifications. In brief, neurons on 12 well plates derived from wild-type and app-/- aplp2-/- stem cells 
were kept in culture for 14 days. All cells were incubated with 1 μl 3[H]-Glutamate (L-[G-3H] Glutamic
acid 9.25 MBq, Amersham Bioscience #3-4900220929) for 1 hour at 37°C. After washing cells twice 
with HANKs buffer (prewarmed at 37°C), medium was collected every 5 min and replaced by fresh 
medium. After 25 min (= 6th fraction) and 45 min (=10th fraction) 50 mM KCl or 100 μM glutamate 
was added. The medium was collected until fraction 12 and the amount of 3[H]was determined by a 
scintillation counter. 
Data analysis was performed using Excel program. To quantify the amount of glutamate being released 
by either cell line, the mean value of fractions 4 and 5 before the stimulation (a) and the mean value of 
fractions 7 and 8 after the stimulation (b) event were taken and the mean was calculated ((a + b)/2). This 
mean value was substracted from the value of fraction 6 (c) which displays the amount of glutamate 
released directly after stimulation. The mean of the values from each single experiment was calculated, 
as well as the standard deviation and standard deviation of the mean. 
2.4 Western Blot
Lysis buffer
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Merck #1.04094.100010%Glycerine (87%)
Fluka #934261%Triton®X-100
Fluka #71381150 mMNaCl
Sigma #T-679150 mMTrizma® base
supplierconcentration
Protease inhibitors were freshly added to the lysis buffer (protease inhibitor cocktail tablets, Roche 
#11836153001).
After washing cells twice with cold PBS, cell extracts were prepared by adding lysis buffer (750 μl for a 
6 cm plate; 300 μl for a well from a 12 well plate). Cells were rinsed with the lysis buffer until they 
detached and the solution was triturated. After centrifugation (4200 rpm, 30 min, 4°C) supernatant was 
collected and aliquots were stored at -80°C until further  use.
Western Blots were performed with the NuPAGE® System from Invitrogen. If not stated differently, all 
reagents and materials were purchased from Invitrogen.
For 20 μl of sample, 5 μl NuPAGE LDS sample buffer (# NP0007), 2 μl NuPAGE reducing agent (# 
NP0004) and x μl sample were prepared. Samples were heated for 10 min at 70°C and loaded onto a 
gel. Volumes loaded were adjusted such that the expression of proteins taken for normalization purpose
were similar (~1.5 μl of 750 μl total protein extract). A protein marker interacting with the secondary 
antibody was used (MagicMark™XP Western Protein Standards #LC5602). The Western transfer was 
performed using the XCell II™ Blot Module on PVDF membranes (# LC2005). 
Washing buffer (TBST, 0.2% Tween)
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Sigma #P-13790.2%Tween® 20
Sigma #T-679125 mMTrizma® base
Fluka #601322.7 mMKCl
Fluka #71381137 mMNaCl
supplierconcentration
The membrane was blocked with 5% milk powder in washing buffer for 1 hour on a shaker at room 
temperature. The primary antibody was added to the membrane in 2% milk powder in washing buffer 
and incubated at 4°C on a shaker over night. After washing several times the secondary antibody was 
added in 2% milk powder in washing buffer and incubated for 1-1.5 hours at room temperature. 
Subsequently, the membrane was washed in washing buffer, incubated with chemiluminescence
detection solution (ECL plus, Amersham Bioscience #25006277) and exposed to Hyperfilm ECL 
(Amersham Bioscience #25800095).
2.5 RT-PCR
2.5.1 RNA isolation
Isolation of RNA was based on the protocol of Chomczynski et al., 1987.
After washing cells twice with cold PBS, they were lysed by adding TRIZOL® Reagent (Invitrogen
#15596-018; 1 ml for a 6 cm plate, 300 μl for one well from a 12 well plate). 0.1 ml chloroform (Sigma 
#C-2432) per ml TRIZOL® was added and the sample was vigorously vortexed and incubated on an
Eppendorf shaker (10 min, 400 rpm). The homogenate was centrifuged (10 min, 14000 rpm, RT) and 
the
the upper aqueous phase containing the extracted RNA was transferred to a fresh tube. An equal volume 
of cold isopropanol (Fluka #59310) was added and the solution was incubated for 10 min on ice. 
Precipitated RNA was collected by centrifugation for 10 min at 14000 rpm. After washing the RNA 
pellet once with 70% ethanol (Fluka #02883) RNA was dried and dissolved in 10 mM Tris (pH 7.5). 
The RNA solution was either stored at -80°C or further processed immediately. To remove traces of 
DNA, the RNA solution was incubated with 5 mM MgCl2 and 10 units DNase (Roche #776 785) for 1h 
at 37°C. To remove DNase, phenol/chloroform extraction was performed by adding 1 volume H2O and 
1 volume phenol:chloroform:isoamyl alcohol 25:24:1 (Sigma #P-3803). The solution was vortexed and 
centrifuged for 5 min at 14000 rpm. The upper phase was collected and 0.3 M sodium acetate (NaAc, 
pH 5.2) and 3 volumes ethanol were added for DNA precipitation. The solution was incubated for 10 
min on ice and centrifuged for 25 min at 14000 rpm at 4°C. After washing the RNA pellet once with 
70% ethanol, pellet was dried and dissolved in 10 mM Tris (pH 7.5). RNA was quantified using the 
ND-1000 machine (NanoDrop Technologies) and aliquots of 400 ng RNA were stored at -80°C.
2.5.2 cDNA Synthesis
For first-strand cDNA synthesis 400 ng of DNase-treated total RNA were mixed with 300 ng random 
primers (Invitrogen #48190-011). To perform primer annealing the solution was incubated at 65°C for 5 
min and slowly cooled down to 25°C (0.1°C/sec). Reverse transcriptase reaction was carried out with 
50 units reverse transcriptase (RT, Stratagene #600085), 0.5 mM dNTPs (Invitrogen #10297-117) and 
50 mM Tris-HCl, 75 mM KCl and 3mM MgCl2 (Stratagene #600085-52) in a final volume of 50 μl. 
The mixture was incubated for 1 h at 42°C and reverse transcriptase was inactivated for 5 min at 90°C. 
The cDNA synthesized as described has a concentration of 8 ng/μl and was diluted to a final 
concentration of 1 ng/μl and stored at -20°C until further use. 
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2.5.3 Semi-quantitative RT-PCR
PCR Master Mix for 50 μl reaction volume: 
1μlcDNA
Invitrogen #18038-0262 unitsTaq Polymerase
Microsynth200 nMreverse primer
Microsynth200 nMforward primer
Invitrogen #18038-0261.5 mMMgCl2 (50 mM)
Invitrogen #10297-117200 nMdNTP
Invitrogen #18038-02620 mM Tris-HCl; 50 mM KClPCR buffer (-MgCl2)
supplierconcentration
For primer sequences see Table II.
PCR amplification protocol:
step 1: 95°C 5 min
step 2: 95°C 1 min
step 3: 63°C 1 min
step 4: 72°C 1 min
step 5: 72°C 2 min
Steps 2-4 were repeated 34 times.
PCR products and 1 kb ladder (US Biological, #03930-11A) were loaded on a 1.5 % agarose (Invitrogen
#15510-027) gel containing 0.5 μg/ml ethidiumbromide (Sigma #E1510). Gel detection was performed 
with Vilber Lourmat gel detection system, a CHOU high performance CCD camera and print outs were 
done with a SONY video graphic printer UP-890 CE.
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2.5.4 Quantitative RT-PCR 
Quantitative RT-PCR was performed using TaqMan® probes. The primers were double-dye
oligonucleotides with FAM as the fluorescent reporter dye at the 5′end and TAMRA as the quencher 
dye at the 3′end. Inventoried assays for detection of vglut2 and synaptophysin transcription were 
purchased from Applied Biosystems (see Table III). Primers and probes for tau, egfp, human APP
(hAPP) and mouse app (ms app) detection were designed using primer express software from ABI
according to manufacturers advices and bioinformatic analysis to isolate specific amplicon sequences. 
They were purchased from Microsynth.
From each RNA sample two to three independent cDNAs were synthesized. With each cDNA two to 
three independent PCRs were performed, using every sample in triplicates.
The following master mixes were prepared for individual genes:
18S transcription
175 nM18S FAM-TAMRA probe 
(6.25 μM)
RT-CKFT-18S; Eurogentec 300 nM18S primer mix (10 μM)
qPCR Master Mix, RT-QP2X-
03; Eurogentec 
1x2xQPC PCR master mix probe 
assay
supplier denotationconcentration
vglut2 or synaptophysin transcription
Mm 00499876_m1 (vglut2);
Mm 00436850_m1 
(synaptophysin);
ABI Applied Biosystems
1xFAM-TAMRA primer mix and 
probe (20x)
qPCR Master Mix, RT-QP2X-
03; Eurogentec 
1x2xQPC PCR master mix probe 
assay
supplier denotationconcentration
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tau, hAPP, ms app or egfp transcription
300 nMPrimer 2 (10 μM)
175 nMFAM-TAMRA probe (0.175 
μM)
Microsynth300 nMPrimer 1 (10 μM)
qPCR Master Mix, RT-QP2X-
03; Eurogentec
1x2xQPC PCR master mix probe 
assay
supplier denotationconcentration
Per 20 μl reaction volume 5 ng cDNA were taken. Quantitative RT-PCR was performed in 96-well plate 
format with an ABI Prism® SDS 7900 HT thermocycler. Minus RT controls were included to check for 
traces of genomic DNA as well as non-template controls to check for primer dimerization.
PCR amplification protocol:
step 1: 50°C 2 min
step 2: 95°C 10 min
step 3: 95°C 15 seconds
step 4: 60°C 1 min
Step 3-4 were repeated 39 times.
2.6 Genotyping
tail buffer
Sigma #L-43900.2 %SDS
Fluka #71381200 mMNaCl
Sigma #E-51345 mMEDTA
Sigma #T-3253100 mM (pH8.5)Trizma hydrochloride
supplierconcentration
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Mouse tails were incubated in tail buffer containing 0.1 μg/μl Proteinase K (Merck #1.24568.0500) on 
an Eppendorf shaker (400 rpm, 55°C over night). The solution was centrifuged (14000 rpm, 1 min) and 
the supernatant was transferred into 500 μl isopropanol. The solution was centrifuged (14000 rpm, 30 
min) and the pellet was washed once with 70% Ethanol. DNA was subsequently dried and resuspended
in 300 μl TE (pH 8). DNA was resuspended by agitation at 55°C over night before performing the PCR.
PCR Master Mix for 50 μl reaction volume: 
1μlDNA
Invitrogen #18038-0262 unitsTaq Polymerase
Microsynth200 nMreverse primer
Microsynth200 nMforward primer 2
Microsynth200 nMforward primer 1
Invitrogen #18038-0261.5 mMMgCl2 (50 mM)
Invitrogen #10297-117200 nMdNTP
Invitrogen #18038-02620 mM Tris-HCl; 50 mM KClPCR buffer (-MgCl2)
supplierconcentration
Primer pair UM42 (for sequence see Table IV) and UM44 detect the app wild-type allele (650 bp
length); primer pair UM42 and P3-hygro detect the targeted allele (430 bp length). Primers aplp2-1 and 
aplp2-2 detect the aplp2 wild-type allele (400 bp length) and primer pair aplp2-1 and aplp2-3 detect the 
targeted allele (350 bp).
PCR amplification protocol for genotyping:
step 1: 95°C 2 min
step 2: 95°C 30 sec
step 3: 63°C 30 sec
step 4: 72°C 30 sec
step 5: 72°C 5 min
Step 2-4 were repeated 34 times.
PCR products were loaded on 1.5 % agarose gels and run at 150 Volt. For detection see semi-
quantitative RT-PCR.
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Table I 
Primary antibodies
Synaptic Systems SySy
#104 201
1:10000 (Western)mousesynaptobrevin/VAMP2
Sigma #S-57681:2000 (Western)mousesynaptophysin
Chemicon International 
#MAB3420
1: 3000 (Western)mousetau-1
Sigma #T-86601:5000 (Western)mouseβ-tubulin isotype III
Chemicon International 
#MAB5502
1:3000 (Western)mouseVGLUT1 (BNPI, vesicular 
glutamate transporter1)
Synaptic Systems SySy
#135 102
1:5000 (Western)rabbitVGLUT2 (DNPI, vesicular 
glutamate transporter2)
Developmental Studies
Hybridoma Bank
1:4 
(Immunocytochemistry)
mouseRC2
Sigma #P-2461: 1000 (Western)mousePSD-95 (post synaptic density 
protein-95
Developmental Studies
Hybridoma Bank
1:100 (Immunocyto-
chemistry)
mousePax6
Developmental Studies
Hybridoma Bank
1:10 
(Immunocytochemistry)
mouserat-401, nestin
Upstate, #06-3061:1000 (Western)rabbitGluR1
BD Biosciences #8367-21:1000 (Western)rabbitEGFP
Signet Laboratories
#9300-02
1:2000 (Western)mousehuman amyloid-β protein 
(clone: 6E10)
P. Paganetti, personal gift1:3000 (Western)rabbitAPP C8 (amyloid-β-precursor 
protein), C-terminal 
Calbiochem #1716161:5000 (Western)rabbitAPLP2 (β-amyloid precursor-
like protein2), C-terminal
Calbiochem #1716151:3000 (Western)rabbitAPLP1 (β-amyloid precursor-
like protein1), C-terminal
supplierdilutionsource
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Secondary antibodies
Jackson Immuno Research 
#211-035-109
1:5000 –
1:10000
Peroxidase conjugated AffiniPure Mouse Anti-
Rabbit IgG (H+L)
Jackson Immuno Research 
#115-035-062
1:10000Peroxidase conjugated AffiniPure Goat Anti-
Mouse IgG (H+L)
Jackson Immuno Research 
#111-165-144
1:500Cy™3-conjugated AffiniPure Goat Anti-Rabbit
IgG (H+L)
Jackson ImmunoResearch
#115-165-062
1:500Cy™3-conjugated AffiniPure Goat Anti-Mouse
IgG (H+L)
Table II
Primers for semi-quantitative RT-PCR (all sequences are written 5′ → 3′)
CGGCATAACGTGACAACTGCCTG TCG GGG ATG GTT TGCvglut2
CTTCGTTCTCCGGATTTTGGTGCCTCTTCTGTCCTCGCCTTCGtau
CAGCGCTGGTGCTTCTCACGCCACCGGCAAGCTTCTTGaplp2
GAACTGGACGCCTCTGTGCGTGAAGAAACGTGGGATGGTGaplp1
reverse primerforward primer
Table III
Primers for quantitative RT-PCR (all sequences are written 5′ → 3′)
unknownunknownunknown18S RNA
cgaTTATCAGGGTtta
aaccgccaccatggt
TAGCCCCCCTGAT
CTTTC CT
CCTCTTCTGTCCTC
GCCTTCTG
hAPP (tau-happ fusion
cDNA)
CGGCGTCGACCTC
CACCACG
TCTGCTGCATCTTG
GAGAGATG
CCCTGGTGATGTT
GAAGAAGAAA
ms app
targeted regionreverse primerforward primer
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NM_009305, exon2-
exon3, probe in 82
unknownunknownsynaptophysin
NM_080853, exon8-
exon9, probe in 1609
unknownunknownvglut2
CTACAAGACCCGC
GCCGAGGTGA
CGATGCCCTTCAG
CTCGAT
CCAGGAGCGCACC
ATCTT
egfp
CACCACAGCTTGC
CACACTAGCCGAT
TGGCCAAGGAAGC
AACAT
GGGCAGCATCGAC
ATGGT
tau
targeted regionreverse primerforward primer
Table VI
Primers for genotyping (all sequences are written 5′ → 3′)
CCATTGCTCAGCGGTGCTGaplp2-3
GCGACCGGAGGAGACGCA
GATCGGGAGCTCGCC
aplp2-2
GCCAAGCTTGAGTCGGTGT
ATCCGTGCT
aplp2-1
CGAGATCAGCAGCCTCTGT
C 
P3-hygro short = primer 5`in 
the inserted PGK-polyA part
GAGACGAGGACGCTCAGTC
CTAG
UM44 short = primer 5`
CACCTGGTTCTAATCAGA
GGC
UM42 short= primer 3`
reverse primerforward primer
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3.1 Isolation and characterization of embryonic stem cells lacking app or app and 
aplp2
3.1.1 Isolation and characterization of ES cells from app-/- and app-/- aplp2-/- mice
Mouse embryonic stem (ES) cell lines lacking APP or APP and APLP2 were isolated from app-/- and 
app-/- aplp2-/- blastocysts which were derived from app-/- and app-/- aplp2-/- mice, kindly provided by 
Prof. U. Müller (MPI für Hirnforschung, Frankfurt/M.; Heber et al., 2000).
App-/- males (genetic background of 129OLAxC57BL/6) were backcrossed with SV129 PasIco females 
for one generation to obtain heterozygote animals. Subsequent crossing of the heterozygote animals 
generated blastocysts from all three genotypes (app+/+, app+/-, app-/-) allowing the isolation of 
different ES cell lines with the same genetic background. In addition, backcrossing with Sv129 lines 
increases the isolation efficiency. Indeed, most of the commonly used ES cell lines are derived from 
strain 129 (Evans et al., 1981).
As app-/- aplp2-/- mice (genetic background of 129Sv(ev)xC57BL/6) are postnatally lethal, app+/-
aplp2-/- animals were crossed to obtain blastocysts with the desired app-/- aplp2-/- genotype for ES cell 
isolation.
Embryonic stem cells were isolated from the inner cell mass (ICM) of blastocysts (Robertson, 1987). 
Females were injected with pregnant mare′s serum (PMS, 5 U/animal) and two days later with human
chorionic gonadotropin (hCG, 5 U/animal) for super-ovulation. Matings were set up directly after the 
last injection (referred to as day 0) and plaques were checked after 4 hours and the next morning. At 
day 3.5 post coitum (pc) blastocysts were collected and plated on mouse embryonic feeder cells 
(MEFs). At day 6.5 pc ICMs were picked, dissociated and plated on new MEFs. ES cell clones were 
picked
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picked between 10.5 and 16.5 days pc. ES cell lines were passaged every second day on MEFs and cells 
were frozen after the second and third passage. For further characterization ES cells were kept in culture 
without feeder cells for up to three passages and genotype (see Materials and Methods; Fig. 2 and Fig. 
3) as well as karyotype were determined. Also, the presence of mycoplasma was checked. 
For the present work three ES cell lines were used: 
- clone 159-2 (wild-type), derived from app+/- crossings
- clone 149-1 (app-/-), derived from app+/- crossings
- clone B8-1 (app-/- aplp2-/-), derived from app+/- aplp2-/- crossings.
All three ES cell lines were male, harbor 40 chromosomes and were negative for mycoplasma.
Results
Figure 2: Genotyping of the wild-type and app-/- ES cell clones
Genotyping of ES cells was performed after the cells had been in culture for several passages without MEFs (see 
Materials and Methods for primer sequences and protocol). Primers for app gene detection amplify a wild-type 
(app+/+) fragment of 650 bp length and a knock-out (app-/-) fragment of 430 bp length. Clone 159-2 shows a 
wild-type fragment and is characterized as wild-type ES cell line (app+/+ ES cell line). Clone 149-1 shows a 
knock-out fragment and therefore lacks the app gene (app-/- ES cell line).
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Figure 3: Genotyping of the app-/- aplp2-/- ES cell clone
Genotyping of ES cells was performed after the cells had been in culture for several passages without MEFs (see 
Materials and Methods for primer sequences and protocol). Primers for app gene detection amplify a wild-type 
(app+/+) fragment of 650 bp length and a knock-out (app-/-) fragment of 430 bp length. Primers for aplp2 gene 
detection amplify a wild-type (aplp2+/+) fragment of 400 bp length and a knock-out (aplp2-/-) fragment of 350 
bp length. Clone B8-1 shows fragments referring to app-/- and aplp2-/- and therefore lacks the app and aplp2
gene (app-/- aplp2-/- ES cell line).
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3.1.2 Characterization of neurons derived from app-/- and app-/- aplp2-/- ES cells
The embryonic stem cell clones 159-2 (wild-type), 149-1 (app-/-) and B8-1 (app-/- aplp2-/-)  were 
differentiated into neurons according to the protocol of Bibel et al., 2004 (further details see Materials 
and Methods).
The absence of APP or APP and APLP2 in neurons derived from app-/- and app-/- aplp2-/- ES cells 
was confirmed by Western Blot analysis (Fig. 4 – Fig. 6). Protein extracts from neurons were taken 3, 5, 
6, 8, 9, 10 and 12 days after dissociation of EBs (referred to as 3, 5, 6, 8, 9, 10 and 12 days in vitro, 
DIV) and equal protein volumes were loaded onto the gel. Expression of APP was tested with an 
antibody raised against the 19 C-terminal amino acids of human APP (APP C8 personal gift P. 
Paganetti, Novartis) that cross-reacts with mouse APP. Also, due to the high sequence homology 
between the three APP family proteins, this antibody might cross-react with APLP1 and APLP2.
APP could not be detected in neurons derived from app-/- and app-/- aplp2-/- ES cells. In wild-type 
neurons, expression of APP increases during the course of neuronal differentiation (Fig. 4).
APLP1 protein expression was found in neurons of all three cell lines (Fig. 5) while APLP2 protein was
Results
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shown to be absent in app-/- aplp2-/- neurons but present in wild-type and app-/- neurons. Its 
expression increases during the course of differentiation (Fig. 6).
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Figure 4: Expression of APP protein in neurons derived from ES cells
Western Blots were performed with protein extracts of wild-type, app-/- and app-/- aplp2-/- neurons lysed after 
3, 5, 6, 8, 9, 10 and 12 days in vitro (d). Equal volumes of protein extracts were loaded on a 7% Tris- Acetate gel 
and separated by SDS-PAGE. After protein transfer membrane was probed with a polyclonal APP antibody that 
recognizes human and mouse APP protein (APP C8) (for antibody dilution and further details see Materials and 
Methods). APP protein was detected between 100-120 kDa and showed increasing levels over time in wild-type 
neurons but was absent in app-/- and app-/- aplp2-/- neurons. 
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Figure 5: Expression of APLP1 protein in neurons derived from ES cells
Western Blots were performed with protein extracts of wild-type, app-/- and app-/- aplp2-/- neurons lysed after 
3, 5, 6, 8, 9, 10 and 12 days in vitro (d). Equal volumes of protein extracts were loaded on a 7% Tris-Acetate gel 
and separated by SDS-PAGE. After protein transfer membrane was probed with a polyclonal APLP1 antibody 
that recognizes the C-terminus of mouse APLP1 protein (for antibody dilution and further details see Materials 
and Methods). APLP1 protein was detected at 95 kDa and was present in neurons derived from all three ES cell 
lines.
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Figure 6: Expression of APLP2 protein in neurons derived from ES cells
Western Blots were performed with protein extracts of wild-type, app-/- and app-/- aplp2-/- neurons lysed after 
3, 5, 6, 8, 9, 10 and 12 days in vitro (d). Equal volumes of protein extracts were loaded on a 7% Tris-Acetate gel 
and separated by SDS-PAGE. After protein transfer membrane was probed with a polyclonal APLP2 antibody 
that recognizes the C-terminus of mouse APLP2 protein (for antibody dilution and further details see Materials 
and Methods). APLP2 protein was detected ~110 kDa and was not present in neurons derived from app-/-
aplp2 -/- cells while wild-type and app-/- neurons show increasing levels of APLP2 expression during course of 
differentiation.
We tested by Western blot and semi-quantitative RT-PCR if a compensatory upregulation of aplp1
occurs in the absence of app and aplp2. Western Blot and RT-PCR were performed with protein and 
RNA extracts respectively, isolated from 12 days old neurons. The volumes of protein extracts were 
normalized to volumes representing equal amounts of tau. APLP1 protein and RNA levels did not 
change in the absence of app and aplp2 (Fig. 7 and Fig. 8). As a result of some variation in the quality 
of independent differentiations, differences in protein levels within one genotype were occasionally 
observed (note for example variations of APLP1 levels in the two independent wild-type 
differentiations shown in Fig. 7). 
These results show that APP and APLP2 were absent in neurons derived from ES cells lacking both 
genes. APLP1 expression was detectable, but it did not show a compensatory upregulation in the 
absence of the two other APP family members. 
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Figure 7: Expression of APP, APLP1 and APLP2 protein in neurons after 12 DIV
Western Blots were performed with protein extracts from two independent differentiations of either genotype. 
Extracts were taken from wild-type and app-/- aplp2-/- neurons after 12 DIV and the volumes of loaded protein 
extract were normalized to volumes representing equal amounts of tau protein. Protein extracts were loaded on 
7% Tris-Acetate gels for detection of APP and APP-related proteins and on a 10% Bis-Tris gel for detection of 
tau protein. Protein separation was performed by SDS-PAGE and after protein transfer membranes were probed 
with antibodies recognizing tau (tau-1), APP (APP C8), APLP1 or APLP2 (for further details see Materials and 
Methods). Tau protein was detected at 50 kDa, APP between 100-120 kDa, APLP1 at 95 kDa and APLP2 at 110 
kDa. APLP1 showed no upregulation in app-/- aplp2-/- neurons compared to wild-type neurons. 
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Figure 8: Analysis of APP, APLP1 and APLP2 transcripts
Semi-quantitative RT-PCR was performed with RNA extracts from two independent differentiations of either 
genotype. RNA was isolated from wild-type, app-/- and app-/- aplp2-/- neurons after 12 DIV and cDNA
synthesized according to standard protocol (for details see Materials and Methods). Primers used for app
detection amplify a fragment of 450 bp length, primers used for aplp1 detection amplify a fragment of 750 bp
length and primers used for aplp2 detection amplify a fragment of 464 bp length.Tau was used as housekeeping 
gene and primers for its detection amplify a fragment of 422 bp length. Note that the levels of aplp1 appear to be 
similar in both genotypes. 
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Neuronal differentiation of ES cells according to our protocol results in an essentially homogenous 
population of neural progenitors with all the characteristics of radial glial cells. In addition, these cells 
express the transcription factor Pax6 (Bibel et al., 2004). Recently, Pax6-positive radial glial cells in the 
developing telencephalon have been found to generate virtually all pyramidal neurons in the developing 
cortex (Malatesta et al., 2003). Likewise, the differentiation of radial glial cells in our system results in 
the generation of glutamatergic neurons (Bibel et al., 2004). These neurons show characteristics 
comparable to those found in the cerebral cortex or hippocampus, as revealed by electrophysiological 
and biochemical criteria.
In addition to the expression of typical radial glial cell markers such as nestin and RC2, APP has been 
shown to be highly expressed in radial glial cells in vivo (Trapp et al., 1994). In line with this, we found 
that our ES cell derived radial glial cells also express high levels of APP (Bibel et al., 2004). 
To investigate whether deletion of app or app and aplp2 would influence the generation of radial glial
cells and their subsequent differentiation in neurons, we characterized the neural progenitors derived 
from ES cells lacking app or app and aplp2 for the presence of nestin, RC2 and Pax6. 
We found that the neural progenitors generated from wild-type and knock-out ES cells show a similar 
morphology. We fixed the cells 2-5 and 24 hours (h) after dissociation of EBs and quantified the 
proportion of cells expressing the markers nestin, RC2 and Pax6 in relation to the total number of cells 
assessed by DAPI- (4′,6′-diamidino-2-phenylindole) staining. Nestin immunostaining resulted in 87.8 ±
7.6% positive app-/- and 91.2 ± 6.8% positive app-/- aplp2-/- cells after 2-5 h compared to 92.1 ± 8.8% 
of positive cells in the wild-type and its expression decreased to 49.6 ± 7% in app-/- and 40 ± 12.8% in 
app-/- aplp2-/- cells and 60.5 ± 14.8% in the wild-type after 24 h (Fig. 9). After 2-5 h 100 ± 0% of app  
-/- and 97.1 ± 3.9% of app-/- aplp2-/- cells were RC2-positive compared to 100 ± 0% positive cells in 
the wild-type. 98.9 ± 1.9% of app-/- and 88.7 ± 12.2% of app-/- aplp2-/- cells were still positive after 24 
h and 100 ± 0% of the wild-type neurons (Fig. 10). 2-5 h after plating 85.9 ± 7.3% of app-/- and 88.1 ±
6% of app-/- aplp2-/- cells were Pax6-positive compared to 93.4 ± 6.6% of the wild-type cells. Its 
expression after 24 h decreased to 60 ± 3.2% in app-/- and 59.4 ± 18.3% in app-/- aplp2-/- cells 
compared to 58.5 ± 10.9% in the wild-type (Fig. 11 and Fig. 12).
3.2 Characterization of neural progenitors derived from ES cells lacking app or app
and aplp2 
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These results indicate that the absence of app or app and aplp2 plays no role with regard to the 
generation of Pax6-positive radial glial cells. Like wild-type cells, the mutant progenitors display  
similar antigenic characteristics. Irrespective of their genotype, they subsequently all differentiate  into 
neurons, as judged by expression of neuron specific markers such as β-tubulin and synaptophysin
(Chapter 3.3). In addition, they develop a homogenous morphology, strongly reminiscent of pyramidal 
neurons after several days in culture.
Results
Figure 9: Quantification of the radial glial cell marker nestin
Neural progenitors derived from wild-type, app-/- and app-/- aplp2-/- ES cells were fixed 2-5 and 24 hours after 
plating of dissociated EBs. Cells were stained with a monoclonal antibody recognizing nestin (rat 401) and with a 
dye, DAPI, forming fluorescent complexes with DNA. Nestin was visualized by staining with a Cy3-conjugated 
secondary antibody (for further details see Materials and Methods). Cells positive for nestin were counted and the 
percentage of positive cells was calculated in relation to the total number of cells (DAPI-positive nuclei). The 
results are expressed as % ± S.D.
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Figure 10: Quantification of the radial glial cell marker RC2 
Neural progenitors derived from wild-type, app-/- and app-/- aplp2-/- ES cells were fixed 2-5 and 24 hours after 
plating of dissociated EBs. Cells were stained with a monoclonal antibody recognizing RC2 and with a dye, 
DAPI, forming fluorescent complexes with DNA. RC2 was visualized by staining with a Cy3-conjugated 
secondary antibody (for further details see Materials and Methods). Cells positive for RC2 were counted and the 
percentage of positive cells was calculated in relation to the total number of cells (DAPI-positive nuclei). The 
results are expressed as % ± S.D.
Figure 11: Quantification of Pax6 expression in radial glial cells
Neural progenitors derived from wild-type, app-/- and app-/- aplp2-/- ES cells were fixed 2-5 and 24 hours after 
plating of dissociated EBs. Cells were stained with a monoclonal antibody recognizing Pax6 and with a dye, 
DAPI, forming fluorescent complexes with DNA. Pax6 was visualized by staining with a  Cy3-conjugated 
secondary antibody (for further details see Materials and Methods). Cells positive for Pax6 were counted and the 
percentage of positive cells was calculated in relation to the total number of cells (DAPI-positive nuclei). The 
results are expressed as % ± S.D.
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3.3 Expression of synaptic proteins in neurons lacking app or app and aplp2
Several studies suggest a contribution of APP and its homologues in synapse formation and function 
(see Introduction). Because our ES cell-derived system allows us to work with neurons that develop in 
synchrony, we decided to investigate a possible role of APP and APLP2 during synapse formation by 
analyzing the expression of synaptic proteins in neurons derived from ES cells lacking app or app and
aplp2. In protein extracts from wild-type, app-/- and app-/- aplp2-/- neurons lysed after 3, 5, 6, 8, 9, 10 
and 12 DIV the expression of well characterized synaptic markers including the presynaptic markers 
synaptobrevin and vesicular glutamate transporter 2 (VGLUT2) and postsynaptic proteins such as 
postsynaptic density-95 (PSD-95) and glutamate receptor subunit 1 (GluR1) was analyzed by Western 
Blot
Figure 12: Pax6 immunoreactivity of radial glial cells derived from wild-type, app-/- and app-/- aplp2-/-
ES cells
Radial glial cells derived from wild-type, app-/- and app-/- aplp2-/- ES cells were fixed after 2-5 and 24 hours and 
stained with a monoclonal antibody recognizing Pax6 and with a dye, DAPI, forming fluorescent complexes with 
DNA. Pax6 was visualized by a Cy3-conjugated secondary antibody (for further details see Materials and 
Methods). Pictures show the staining pattern of Pax6 as overlay of phase contrast and fluorescence images of the 
nuclear marker Pax6 and DAPI. In blue: DAPI, in purple: Pax6 and DAPI.
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Blot. Protein amounts were adjusted such that the expression of the neuron specific markers β-tubulin
or tau were similar. Comparable levels of synaptobrevin and GluR1 (Fig. 13) where found, while the 
expression of PSD-95 was slightly reduced in lysates from app-/- and app-/- aplp2-/- neurons. By 
contrast, a remarkable reduction in the expression of VGLUT2 could be observed in neurons lacking 
app as well as app and aplp2. Reduction of VGLUT2 expression seemed to be more significant in 
app-/- aplp2-/- than in app-/- neurons (Fig. 13) suggesting a gene dosage dependency. However,
decrease of VGLUT2 in app-/- neurons was not always consistent, possibly due to the presence of 
APLP2. In view of this, we subsequently focused on the comparison of wild-type versus app-/- aplp2-/-
neurons.
According to previous electrophysiological recordings (Bibel et al., 2004) we considered neurons after 
12 DIV as having mature synapses and therefore, all further studies were performed with neurons that 
had been in culture for at least 12 days (12 DIV).
Figure 13 (next page): Expression of synaptic proteins in wild-type, app-/- and app-/- aplp2-/- neurons 
Western Blots were performed with protein extracts taken from wild-type, app-/- and app-/- aplp2-/- neurons after 
3, 5, 6, 8, 9, 10 and 12 DIV. Volumes of protein extracts loaded on 10% Tris-Bis gels were normalized to 
volumes representing equal amounts of β-tubulin protein. After protein transfer the membranes were either probed 
with a monoclonal antibody recognizing synaptobrevin/VAMP2 (18 kDa), a polyclonal antibody 
recognizing VGLUT2 (~65 kDa), a monoclonal antibody recognizing PSD-95 (95 kDa) or a polyclonal 
antibody recognizing the glutamate receptor subunit 1, GluR1 (100 kDa). For normalization a monoclonal 
antibody recognizing the neuron specific β-tubulin was used (50 kDa) (for antibody dilutions and further details 
see Materials and Methods). VGLUT2 and PSD-95 appear differentially expressed whereas synaptobrevin and 
GluR1 do not.
Results
wt wt wt wtap
p -
/-
ap
p -
/-
ap
p -
/-
ap
p -
/-
ap
p -
/-
ap
lp2
 -/
-
ap
p -
/-
ap
lp2
 -/
-
ap
p -
/-
ap
lp2
-/-
ap
p -
/-
ap
lp2
-/-
β-tubulin
3d 5-6d 8-9d 10-12d
50 kDa -
synaptobrevin20 kDa-
PSD-95
80 kDa-
GluR1100 kDa-
VGLUT250 kDa-
39
Western Blots with extracts from wild-type and app-/- aplp2-/- neurons after 12 DIV normalized for 
similar levels of tau showed a strong decrease in VGLUT2 expression while synaptophysin did not 
seem to be changed (Fig. 14). The reduction of VGLUT2 protein expression was confirmed in 7 
independent differentiations of ES cells lacking APP and APLP2 compared to 6 independent 
differentiations of wild-type neurons.
The expression of VGLUT1, another vesicular glutamate transporter, was also tested in wild-type and 
app-/- aplp2-/- neurons. It showed a very similar expression pattern as VGLUT2 that led us to doubt the 
specificity of the VGLUT1 antibody (data not shown). As both transporters are strongly related in their 
amino acid sequence (82%) the antibodies might cross-react.
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Figure 14: Expression of synaptic proteins in wild-type and app-/- aplp2-/- neurons after 12 DIV
Western Blots were performed with protein extracts from wild-type and app-/- aplp2-/- neurons after 12 DIV. 
Volumes of protein extracts loaded on 10% Tris-Bis gels were normalized to volumes representing equal amounts 
of tau protein. After protein transfer the membranes were either probed with a polyclonal antibody recognizing 
VGLUT2 (~65 kDa), a monoclonal antibody recognizing synaptophysin (38 kDa) or a monoclonal antibody 
recognizing the neuron specific β-tubulin (50 kDa). For normalization a monoclonal antibody recognizing tau
(tau-1; ~50 kDa) was used (for antibody dilutions and further details see Materials and Methods). Note the strong 
reduction in VGLUT2 expression in app-/- aplp2-/- neurons.
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The observed reduction of VGLUT2 protein could be either the result of changes in vglut2 transcription 
or translation. To investigate if the transcription of vglut2 is altered in the absence of app and aplp2, we 
performed quantitative RT-PCR and compared the levels of vglut2 transcript in wild-type and double 
knock-out neurons. We included synaptophysin as a control, as we did not observe any change at the 
protein level. RNA was isolated from wild-type and app-/- aplp2-/- neurons after 12 DIV and 
quantitative RT-PCR was carried out using the TaqMan system as described in Materials and Methods. 
RNA levels of vglut2 and synaptophysin genes were normalized to tau. Tau RNA levels were 
normalized to 18S ribosomal RNA (18S). 
By comparing 5 independent wild-type with 10 independent app-/- aplp2-/- differentiations we detected 
a strong decrease in the transcription of the vglut2 gene in neurons lacking app and aplp2 while
synaptophysin transcription was not significantly changed (Fig. 15 and Fig. 16). Variations in tau as 
well as in synaptophysin RNA levels could be observed, presumably due to fluctuations of culture 
quality. However, these variations had no influence on the reduction of VGLUT2 RNA levels. The 
results of the quantitative RT-PCR were supported by semi-quantitative RT-PCR data, where a strong 
reduction in the vglut2 transcription could be observed as well (Fig. 17). 
As we were not able to clearly identify VGLUT1 at the protein level because of a possible cross-
reactivity of the antibody with VGLUT2, we examined the presence of VGLUT1 at the RNA level. 
Therefore, we performed quantitative RT-PCR for vglut1 transcripts. As the levels detected in wild-type 
and double knock-out neurons were only slightly above background levels (data not shown), we 
conclude that the vglut1 gene is expressed in neurons derived from both ES cell lines only at very low 
copy numbers. This result further suggests that the VGLUT1 antibody very likely recognizes VGLUT2 
in Western blot experiments.
Thus, we conclude that the deletion of app and aplp2 affects transcription of vglut2 and that the 
reduction of VGLUT protein is accounted for a reduction in VGLUT2, as opposed to VGLUT1, which 
seems to be expressed at very low levels. 
3.4 Vglut2 transcription in wild-type and app-/- aplp2-/- neurons 
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Figure 15: Vglut2 transcription in wild-type and app-/- aplp2-/- neurons assessed by quantitative RT-
PCR
Transcription of tau and vglut2 in wild-type and app-/- aplp2-/- neurons after 12 DIV was performed using 
quantitative RT-PCR. RNA was isolated and cDNA synthesis performed as described in Materials and Methods. 
Transcription of vglut2 and tau was assessed using inventoried assays from Applied Biosystems and primers and 
probe designed with primer express software from ABI, respectively. Vglut2 transcription was normalized to tau
transcription while tau itself was normalized to 18S. Results from 3 independent PCRs performed with one cDNA
are shown as mean of 4 independent differentiations of either genotype ± S.D. Note the strong decrease of vglut2
transcription in app-/- aplp2-/- neurons normalized to tau. 
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Figure 16: Synaptophysin transcription in wild-type and app-/- aplp2-/- neurons assessed by quantitative
RT-PCR
Transcription of tau and synaptophysin in wild-type and app-/- aplp2-/- neurons after 12 DIV was performed 
using quantitative RT-PCR. RNA was isolated and cDNA synthesis performed as described in Materials and 
Methods. Transcription of synaptophysin and tau was assessed using inventoried assays from Applied Biosystems
and primers and probe designed with primer express software from ABI, respectively. Synaptophysin
transcription was normalized to tau transcription while tau itself was normalized to 18S. Results from 3 
independent PCRs performed with one cDNA are shown as mean of 4 independent differentiations of either 
genotype ± S.D. Synaptophysin RNA levels were not significantly different between wild-type and app-/-
aplp2   -/- neurons normalized to tau.
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Figure 17: Vglut2 transcription in wild-type and app-/- aplp2-/- neurons assessed by semi-quantitative RT-
PCR
Transcription of vglut2 in wild-type and app-/- aplp2-/- neurons after 12 DIV was performed using semi-
quantitative RT-PCR. RNA was isolated and cDNA synthesis performed as described in Materials and Methods. 
Primers for tau detection amplify a fragment of 422 bp length and primers for vglut2 detection amplify a fragment 
of 594 bp length. Note the strong decrease in VGLUT2 RNA levels in app-/- aplp2-/- neurons.
3.5 Release of glutamate in wild-type and app-/- aplp2-/- neurons
VGLUT1 and VGLUT2 are the main vesicular glutamate transporters in glutamatergic neurons. As our 
results indicate, only VGLUT2 is expressed at appropriate levels in our ES cell system and is strongly 
reduced after 12 DIV in app-/- aplp2-/- neurons. Therefore it was of interest to test if the release of
glutamate is affected in these cells. To explore this possibility, we investigated the glutamate release of 
wild-type and double knock-out neurons.
Neurons after 14 DIV were incubated with 3[H]-labeled glutamate (3[H]-glu) and the subsequent release 
of 3[H]-glu after stimulation was monitored. The neurons were stimulated either with KCl (50 mM) or 
glutamate 
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glutamate (glu, 100 μM; for further details see Materials and Methods). KCl leads to a general 
depolarization of neurons by increasing the intracellular [Ca2+]i concentrations, while glutamate causes 
a more local depolarization through the activation of glutamate receptors. Stimulation by either means 
result in neurotransmitter release. Neurons were stimulated twice (after 25 and 45 min) and medium 
fractions were collected before and after stimulation, to compare counts of 3[H]-glu between the two 
genotypes (Fig. 18). 
Figure 18: Experimental paradigm for glutamate release assay
Diagram of the experimental set-up for measuring glutamate release. Neurons (14 DIV) were incubated for 1 hour 
with 3[H]-glu at 37°C. Cultures were washed several times with HANKS buffer before medium fractions were 
collected every 5 min and replaced by fresh medium. After 25 and 45 min KCl or glutamate was added. The 
fractions were analyzed with a scintillation counter. Stars depict the expected progression of 3[H]-labeled
glutamate release.
Without application of depolarizing concentrations of KCl or glutamate, a slow decline of 3[H]- glu in 
the collected fractions was observed related to glutamate release after spontaneous neuronal activity 
(Fig. 19). In contrast, after the neurons had been stimulated for the first time, significant amounts of 
labeled glutamate were released, while the amount released after the second stimulus was much lower 
as the system depletes of 3[H]-glu (Fig. 19). The comparison of the amounts of labeled glutamate 
released by neurons from both genotypes reveals a clear decrease in the release ability of neurons 
lacking app and aplp2, both after KCl and glutamate stimulation (Fig. 20).
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Thus, the reduction in VGLUT2 expression results in a functional readout and we conclude that the 
decrease in glutamate release is a consequence of the combined absence of APP and APLP2.
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Figure 19: Glutamate release of wild-type and app-/- aplp2-/- neurons
Example of a representative glutamate release curve. A) Wild-type neurons (wt) loaded with 3[H]-glu, were 
stimulated (pink curve) or not (blue curve) with glutamate (100 μM). The stimulation pulse was given after 
fraction 5 and 9 and resulted in an increase in glutamate in fraction 6 and 10. Without stimulation 3[H]-glu was 
released slowly over time. B) Neurons lacking app and aplp2 were treated as the wild-type neurons in A) but 
showed a reduced glutamate release peak in fraction 6 and 10 after stimulation compared to wild-type neurons.
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Figure 20: Quantification of glutamate release
Counts of released 3[H]-labeled glutamate after the first stimulation were compared between wild-type (wt) and 
app-/- aplp2-/- neurons (for analysis paradigm see Materials and Methods). Experiments are shown as mean ±
S.E. of two to three independent differentiations. Glutamate release is strongly reduced in app-/- aplp2-/- neurons 
either after KCl or glutamate stimulation.
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3.6 Vglut2 transcription after γ-secretase inhibitor treatment
The observed reduction in vglut2 transcription suggests a contribution of the two APP family members 
in transcriptional regulation. Recently, a small intracellular fragment of APP and APLP2 (AICD and 
ALICD2; Passer et al., 2000; Scheinfeld et al., 2002), generated by γ-secretase cleavage, has been 
shown to function as a transcriptional regulator (Cao et al., 2001). 
Our finding led us to the hypothesis that vglut2 might be a target gene for the AICD modulated 
transcriptional process.
To get insight into the mechanism involved, we attempted to block the generation of the AICD 
fragment by treating wild-type neurons with a γ-secretase inhibitor. γ-secretase is known to cleave a 
broad range of transmembrane proteins including Notch that is involved in cell-fate determination. As 
we can not exclude an impairment of the Notch pathway by the inhibitor we used, we treated the cells 
after they had been in culture for at least 6 days and already display neuronal characteristics. Wild-type 
neurons were treated with LY411575 (50 nM), a highly potent γ-secretase inhibitor with an IC50 of < 1
nM in HEK cells (Schmidt 2003; Larbig et al., 2004). The inhibitor was applied either only after 6 DIV, 
11 DIV or 6 and 11 DIV and RNA was extracted after 12 DIV. Levels of vglut2 and synaptophysin
transcripts were evaluated by quantitative RT-PCR and normalized to 18S. 6 independent wild-type 
cultures were treated with γ-secretase inhibitor and in 5 of them we could see a decrease in vglut2
transcription, while the transcription of synaptophysin was not affected (Fig. 21). Treatment for 6 days 
in vitro led to a stronger inhibition than only treating after 11 days. However, degree of downregulation
was found to be varying for reasons that are not entirely clear.
Nonetheless, we feel that these findings support the possibility that vglut2 may be regulated at the 
transcriptional level by a proteolytical product of APP and/or APLP2. 
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Figure 21: Treatment of wild-type neurons with γ-secretase inhibitor
Wild-type (wt) neurons were treated with 50 nM γ-secretase inhibitor after 6, 11, or 6 and 11 days in vitro. RNA 
was extracted after 12 DIV and cDNA was synthesized as described in Materials and Methods. Vglut2 and 
synaptophysin transcription were evaluated by quantitative RT-PCR using inventoried detection assays from 
Applied Biosystems. Figures depict the transcription profile of one treated culture. Bars show mean of 3 
independent PCRs performed from one cDNA +/- S.D. Note the reduction of vglut2 transcription normalized to 
18S after treatment with γ-secretase inhibitor while synaptophysin transcription was not changed.
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3.7 Levels of VGLUT2 protein and RNA in neurons expressing human APP in 
addition to endogenous mouse APP
As our findings suggest an involvement of APP and APLP2 in vglut2 transcription, we were interested 
to see if the presence of additional APP at early time points of neuronal development would give rise to 
the opposite effect, that is an increase in vglut2 transcripts and protein. 
To test this possibility, we made use of an ES cell line, termed E3#8, expressing human APP (hAPP) in 
addition to endogenous mouse APP. The E3#8 ES cell line was generated by targeting the cDNA for
hAPP into the locus encoding the microtubule-binding protein tau. Using this strategy, the expression of
hAPP is driven by the endogenous tau promoter. In addition to hAPP the second tau allele was targeted 
with the cDNA for enhanced green fluorescent protein (EGFP) (tautau:egfp/tau:hAPP) and thus neurons 
derived from this cell line express hAPP and EGFP driven by the endogenous tau promoter. As wild-
type line we used ES cells expressing only EGFP driven by the endogenous tau promoter (tautau:egfp/tau; 
named E3) which enabled us to normalize all data to similar levels of EGFP. The E3#8 cell line had 
already been successfully used for human Aβ40 detection by a highly sensitive ELISA (data not shown). 
The production of Aβ40 confirms the presence of human APP protein in the neurons and its cleavage by 
endogenous β- and γ-secretase.
Following their differentiation in neurons, we wanted to study if in the E3#8 cell line additional APP 
protein would increase the transcription of vglut2 and result in higher levels of VGLUT2 protein. As 
APP expression increases strongly during the course of neuronal differentiation we decided to examine 
neurons at early time points. At day 4, the tau promoter has been shown to be already active and human 
APP is transcribed while endogenous mouse APP has not yet reached a stable level. Therefore, 
additional protein might exert an effect on vglut2 transcription at this time point that can be monitored. 
In addition, according to our Western data VGLUT2 protein can be first detected after 5-6 DIV 
(Chapter 3.3). Accordingly, we studied the levels of vglut2 transcript and VGLUT2 protein from 
neurons that had been in culture for 5, 6 and 8 days. We performed quantitative RT-PCR and observed 
in 4 out of 5 independent differentiations a clear increase in vglut2 transcription after 6 DIV in neurons 
derived from E3#8 ES cells compared to E3 derived neurons (Fig. 22). Western Blot analysis did show 
increased VGLUT2 protein levels in some, but not all neurons derived from E3#8 compared to neurons 
derived
Results
derived from E3 (Fig. 23). Because of the time delay between gene transcription and protein 
synthesis we might have missed the optimal time window to detect a possible increase in protein 
level in all neurons examined.
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Figure 22: Vglut2 transcription in neurons derived from E3 and E3#8 ES cells assessed by quantitative RT-
PCR
Transcription of vglut2 in neurons derived from E3 and E3#8 was evaluated using quantitative RT-PCR. RNA 
was extracted from neurons after 5, 6 and 8 DIV and cDNA was synthesized as described in Materials and 
Methods. Vglut2 and egfp transcription was assessed using inventoried assays from Applied Biosystems and 
primers and probe designed with primer express software from ABI, respectively. Vglut2 transcription was 
normalized to egfp, while egfp was normalized to 18S RNA levels. Note the increase of vglut2 transcripts after 6 
DIV.
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Figure 23: Detection of VGLUT2 protein 
levels in neurons derived from E3 and 
E3#8 ES cells by Western Blot analysis
Western Blot analysis was performed with 
protein extracts from neurons derived from
E3 and E3#8, after 5, 6 and 8 DIV. Volumes
of protein extracts loaded on 10% Tris-Bis
gels were normalized to volumes 
representing equal amounts of EGFP protein. 
After protein transfer the membranes were 
either probed with a polyclonal antibody 
recognizing VGLUT2 (~65 kDa) or a
polyclonal antibody recognizing EGFP (~35
kDa) (for antibody dilutions and further 
details see Materials and Methods). Note the 
slight increase of VGLUT2 protein after 6 
DIV in these samples.
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It seems that neurons derived from E3#8 ES cells express hAPP in addition to endogenous mouse APP, 
but that the total amount of APP is not significantly increased compared to wild-type levels. Therefore, 
we are not able to unambiguously link the increased vglut2 transcription to additionally expressed 
hAPP. 
To prove that the increase in vglut2 transcription correlates with increased levels of APP, we performed 
Western blot analysis with an antibody specific for human APP (6E10). In protein extracts isolated 
from neurons after 5, 6 and 8 DIV, increasing levels of human APP could be observed (Fig. 24). 
However, when we investigated the amount of total APP (human and endogenous mouse APP) with an 
antibody recognizing APP from both species (APP C8) we were not able to detect higher levels of total 
APP in neurons derived from E3#8 ES cells compared to wild-type neurons (Fig. 25). 
220 kDa -
80 kDa -
100 kDa -
120 kDa -
5d 6d 8d 5d 8d6d
E3 E3#8
APP 
Figure 24: Detection of human APP levels in neurons derived from E3 and E3#8 ES cells by Western Blot 
analysis
Western Blot analysis was performed with protein extracts from E3 and E3#8 neurons after 5, 6 and 8 DIV. Equal 
volumes of protein extracts were loaded on a 10% Tris-Bis gel. After protein transfer the membrane was probed 
with a polyclonal antibody recognizing the amyloid β sequence of human APP (6E10). 10-fold more protein than 
usually was loaded (for antibody dilution see Materials and Methods) and the APP protein was detected between 
100–120 kDa. Increasing amounts of human APP were detected during the course of differentiation in neurons 
from E3#8 ES cells while neurons from E3 ES cells did not show a specific band at the expected molecular 
weight.
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Figure 25: Detection of total APP protein levels in neurons derived from E3 and E3#8 ES cells by Western 
Blot analysis 
Western Blots were performed with protein extracts from E3 and E3#8 neurons after 5, 6 and 8 DIV. Volumes of 
protein extract loaded on 10% Tris-Bis gels were normalized to volumes representing equal amounts of EGFP 
protein. After protein transfer the membranes were either probed with a polyclonal antibody recognizing EGFP 
(~35 kDa) or with a polyclonal antibody recognizing the C-terminus of human and mouse APP (APP C8) (for 
antibody dilutions and further details see Materials and Methods).
Note that there is no detectable increase in total amount of APP in extracts from E3#8 compared to E3. 
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Discussion
The main finding obtained during the course of this studies is an altered expression of synaptic 
components such as vesicular glutamate transporters (VGLUTs) and postsynaptic density proteins in 
neurons derived from ES cells lacking both app and aplp2. In addition, γ-secretase inhibitor 
experiments suggests that cleavage of APP and APLP2 and the release of their cytoplasmic domain is 
needed for appropriate transcription of the corresponding genes.
4.1 Vesicular glutamate transporters (VGLUTs)
Recently, a highly conserved family of vesicular glutamate transporters, consisting of VGLUT1, 
VGLUT2 and VGLUT3, has been cloned and functionally characterized (review Fremeau et al., 2004). 
These transporters are mainly localized on the membrane of synaptic vesicles in glutamatergic neurons, 
but they are also present in astrocytes (Montana et al., 2004). In neurons they mediate glutamate uptake 
from the presynaptic lumen into the vesicles. The uptake is driven by a proton-based electrochemical 
gradient generated by a vacuolar H+-ATPase. The three transporters share high sequence similarities 
(VGLUT1 and VGLUT2 have a 82% amino acid identity and 92% similarity). They are also highly 
similar with respect to substrate specificity, kinetics and pharmacology. They only recognize glutamate, 
but not aspartate and show a biphasic dependence on chloride concentration. In contrast to these 
similarities, in situ hybridization experiments reveal a complementary expression pattern in the adult 
brain. VGLUT1 is predominantly found in the cerebral cortex, hippocampus and cerebellum, whereas 
VGLUT2 is prominent in diencephalon, brainstem and spinal cord. Although the majority of neurons 
express only one isoform, some co-expression has been described e.g. in primary sensory neurons or
cerebellar mossy fiber terminals (Fremeau et al., 2001). Surprisingly, VGLUT3 is found mainly in 
neurons not considered to be glutamatergic, but cholinergic, serotonergic or GABAergic. Also, its
subcellular 
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subcellular localization differs from its two relatives. While VGLUT1 and VGLUT2 are mostly found 
in nerve terminals, VGLUT3 is additionally localized in cell somata and dendrites, suggesting further 
roles for glutamate, e.g. in retrograde synaptic signaling (Fremeau et al., 2002). 
Interestingly, VGLUT1 and VGLUT2 undergo transcriptional regulation during development resulting 
in a switch from VGLUT2 to VGLUT1 expression in the hippocampus, cortex and cerebellum. In the 
cerebellum for example, VGLUT2 is predominantly found in parallel and climbing fibers at early 
postnatal stages and starts to be downregulated at postnatal day 7 while VGLUT1 starts to be 
upregulated at the same time. Around postnatal day 30, VGLUT1 is the most prominent vesicular 
glutamate transporter found in the cerebellum whereas VGLUT2 only remains present in climbing 
fibers (Miyazaki et al., 2003). The reason for the developmental switch in transporter subtypes and for 
their complementary expression pattern in the adult organism is not yet fully understood. One possible 
explanation could be the mode of glutamate release of the synapses the transporters are located to. 
VGLUT1 is mostly found at synapses showing a low probability of transmitter release, while VGLUT2 
is localized to synapses with a higher release probability. Thus, both transporters may contribute to 
different aspects of synaptic transmission beyond their identified role of glutamate uptake (review 
Fremeau et al., 2004). 
In the present work we found reduced levels of VGLUT in neurons lacking both app and aplp2. Due to 
possible antibody cross-reactivity across the different VGLUT isoforms, we were not able to 
unambiguously identify the affected VGLUT isoform at the protein level. However, the quantitative 
RT-PCR data strongly suggest that vglut2 transcription is clearly and specifically downregulated in   
app-/- aplp2-/- neurons, while vglut1 transcription was comparably low in both wild-type and double 
knock-out neurons. Therefore, we conclude that the observed reduction of vesicular glutamate 
transporter can largely be attributed to altered expression of the VGLUT2 isoform. The low detection of 
vglut1 transcript in our neurons after 12 DIV is consistent with the reported developmental switch from 
VGLUT2 to VGLUT1 occurring in postnatal neurons in vivo, as the neurons probably did not yet reach 
the developmental stage in vitro where the subtype switch takes place. The changes in vglut2
transcription were observed after the neurons had been in culture for at least 12 days. At this time point 
a clear decrease of transcription was detected in the double knock-out neurons. We did not investigate if 
this decrease represents a massive delay in development that would subsequently reach wild-type levels 
at later time points or if we observe a permanent downregulation. This question is of particular 
importance in the 
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importance in the context of future in vivo work. Indeed, in our cell culture system neuronal 
differentiation occurs largely in a synchronous manner which facilitates the kind of observations 
reported here. But in vivo, diverse neuronal populations differentiate at rates that regionally differ, a 
feature that could potentially complicate the analysis of transient versus permanent changes in gene 
expression. Initially, we also included the app single knock-out cells in our study and observed a 
decrease in VGLUT2 protein level that was less clear than the decrease observed in neurons lacking app
and aplp2. In addition, the protein levels of VGLUT2 in the app-/- neurons showed substantial 
variations between experiments, perhaps as a consequence of the suspected partial redundancy between 
the three members of the family. In view of this, we only performed a limited number of experiments 
with the app single knock-out cells.
Of special relevance to the present work is the demonstration that the amount of glutamate transported 
in synaptic vesicles depends on the number of VGLUT1 molecules present per vesicle (Wilson et al., 
2005). The amount of released glutamate can therefore be at least in part dictated by the number of 
VGLUT transporter molecules. The expression of the transporter itself is developmentally regulated, 
activity-dependent and furthermore increases during synapse maturation. This suggests the existence of 
a mechanism by which VGLUT could regulate the functional dynamic range of glutamatergic synapses.
Recently, the role of VGLUT1 in excitatory transmission has been clearly demonstrated by deletion of 
the vglut1 gene in mice (Fremeau et al., 2004; Wojcik et al., 2004). The absence of the transporter 
resulted in either silent synapses or synapses with reduced spontaneous or evoked responses. 
Comparable studies with mice lacking vglut2 have not been published so far. 
Our observation that decreased levels of vesicular glutamate transporter in neurons lacking app and 
aplp2 result in less glutamate release is in line with the results obtained by Wilson et al. (2005). The 
reduced levels of vglut2 transcripts can be expected to result in less transporter present in the vesicles 
which is likely to influence the uptake and release of glutamate. In line with this, following loading of 
our cells with 3[H]-labeled glutamate, we found that less glutamate was released after application of 
depolarizing concentrations of KCl or glutamate. As could be expected, the release was not fully 
abolished since detectable levels of transporters were still found in double knock-out neurons. The 
reduced transmission did not change the survival of the neurons since we were able to keep them in 
culture for similar time periods as the wild-type cells without observing obvious signs of cell death. 
However, as glutamate is the most prominent neurotransmitter in the nervous system changes in its 
availability
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availability at certain time points of development in vivo might result in severe synaptic dysfunctions 
that can conceivably compromise the survival of newborn animals in the first weeks after birth. The 
absence of the vglut1 gene, for example, results in lethality of the animals between postnatal day 18 and 
21 (Wojcik et al., 2004). While they display no abnormalities in the first two weeks after birth 
compared to their littermates, the animals start to differ with the beginning of the third week. They lag 
behind in growth, develop movement disorders and emaciate. Although the cause of death remains 
unclear it occurs around the time when the subtype switch from VGLUT2 to VGLUT1 takes place. The 
survival of the VGLUT1 deficient animals until the end of the third postnatal week and the normal 
development during the first two weeks, emphasizes the predominance of VGLUT2 driven
glutamatergic transmission during early brain maturation. The progressive lack of glutamate 
transmission in areas of the brain such as the hippocampus and the cortex, as well as in peripheral 
systems could result in malfunction of organs, leading to the lethal phenotype of the animals.
Taken together, the vesicular glutamate transporters seem to play a crucial role during early brain 
development and reduced levels are likely to lead to severe synaptic dysfunction. Therefore, the 
observed decrease of VGLUT2 expression in the absence of app and aplp2 could be one explanation for 
the early postnatal lethality of the app-/- aplp2-/- mice.
Indeed, the parallels between the app-/- aplp2-/- and the vglut1-/- animals are intriguing, as both mouse 
models show a lethal phenotype without displaying gross histological abnormalities in the brain or other 
organs. Recent studies performed with app-/- aplp2-/- animals (Wang et al., 2005; Yang et al., 2005; 
Chapter 4.4 of the Discussion) revealed a presynaptic phenotype that results in changes of synaptic 
transmission and reduced synaptic vesicle numbers in synapses of neuromuscular junctions and
submandibular ganglia. Changes in synaptic transmission and reduced numbers of synaptic vesicles 
have been shown for vglut1-/- animals as well (Fremeau et al., 2004; Wojcik et al., 2004).
Experiments to confirm the decrease of vglut2 transcription in the app-/- aplp2-/- animals are currently 
in progress.
Glutamate transmission and vesicular glutamate transporters are also involved in mechanisms outside 
the central nervous system. For example, there is compelling evidence for the expression and function 
of glutamate as a signaling molecule in the digestive system (review Li et al., 2005). Recently, presence 
of VGLUT1 and VGLUT2 in the enteric nervous system and pancreatic tissue has been reported. 
Glutamate release seems to be involved in modulation of digestive mechanisms such as acid secretion 
in
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in the stomach or contractility in the gastrointestinal tract. In the pancreas, glutamate has been found to 
act as an intracellular messenger in glucose-induced insulin exocytosis and glucagon exocytosis. 
VGLUT1 and VGLUT2 were shown to be differential regulated by glucose levels in pancreatic cells 
and seem to take part in the regulated secretion of insulin (review Li et al., 2005). The recent evidence 
for glutamate and VGLUTs being involved in non-neuronal pathways such as hormone release, might 
provide an additional explanation for the lethality of the vglut1-/- animals. The absence of VGLUT1 in 
pancreatic tissue could lead to changes in hormone secretion resulting in the shutdown of organs. Thus, 
the lethal phenotype of vglut1 knock-out animals could be the result of an accumulation of several 
disrupted glutamate release mechanisms, both neuronal and non-neuronal. The same could hold true for 
the app-/- aplp2-/- animals.
4.2 Changes of PSD-95 in neurons lacking app and aplp2
In addition to the reduced expression of the presynaptically localized VGLUT2, we observed decreased 
levels of the postsynaptic protein PSD-95 (postsynaptic density-95) in neurons lacking app and aplp2. 
PSD-95 is part of a highly organized structure found adjacent to the postsynaptic membrane of 
excitatory synapses. It is involved in the structural organization of postsynaptic signaling complexes by 
interaction with membrane proteins such as NMDA receptors and cytoplasmic signaling molecules. In 
particular, it is involved in processes of synapse assembly and maturation as well as synaptic 
transmission and plasticity (Kim et al., 2004). We did not further investigate the changes of PSD-95 in 
our system as we decided to focus on the more prominent decrease of the vesicular glutamate 
transporter. In particular, we do not know at this time point if the reduced expression of PSD-95 is a 
consequence of the presynaptic alterations or if it is a process occurring independently from the vglut2
phenotype. However, in addition to the presynaptic alteration, based on the PSD-95 data we suspect that 
the function of excitatory synapses may be affected in the absence of app and aplp2 as a result of both 
pre- and postsynaptic changes.
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4.3 The APP intracellular domain and transcriptional modulation
The observed decrease in vglut2 transcription raises the question of a possible mechanistic link between 
these changes and the presence or absence of app and aplp2. Recently, the existence of a small (6 kDa) 
C-terminal fragment, called APP intracellular domain (AICD), has been reported (Passer et al., 2000). 
The AICD is generated by proteolytic cleavage at the ε-cleavage site, located ~7 amino acids next to the
amyloid β cleavage site, in the transmembrane region of the protein. Its generation is presenilin-
dependent and most publications referred to it as γ-secretase mediated cleavage, although there is some 
evidence for γ- and ε- independent catalytic events (Chen et al., 2002; Kume et al., 2004). For 
simplicity, we will refer to γ-secretase mediated cleavage when referring to the generation of AICD.
In analogy with Notch, AICD is thought to mediate a similar signaling function for APP and its 
relatives. Notch is a type I transmembrane protein, acting as a membrane-bound transcription factor that 
regulates cell-fate determination during development (review Selkoe & Kopan, 2003). The
heterodimeric-receptor Notch is targeted to the cell surface. After binding to its ligands from the 
Delta/Jagged family, two subsequent cleavages occur mediated by metalloproteases of the ADAM 
family and γ-secretase respectively, finally resulting in the release of the Notch intracellular domain 
(NICD) into the cytoplasm. The NICD translocates to the nucleus and associates with a DNA-binding 
protein called CSL (CBF1, Suppressor of Hairless and Lag-1). In the absence of the NICD, CSL acts as 
repressor of transcription and is bound to several proteins such as SMRT (Silencing Mediator of 
Retinoid and Thyroid hormone receptor) and HDAC (histone deacetylase). Upon binding of NICD to 
CSL, the latter converts from a transcriptional repressor to an activator. The SMRT/HDAC complex 
dissociates and histone acetylases can be recruited to assist chromatin remodeling and initiate 
transcription of target genes such as HES genes. The signaling function of the NICD is controlled by
phosphorylation and ubiquitination that results in the degradation of the intracellular domain and resets 
the cell again to a basal state until the next signaling cascade is started.
The elucidation of the Notch signaling pathway provided the basis for further work related to the 
possible mechanism used in the context of APP signaling. The first evidence for a role of the AICD in 
transcriptional regulation was obtained by Cao et al. (2001) using a heterologous reporter system. 
Fusion of APP with DNA binding domains of either yeast (Gal4) or bacterial (LexA) transcription 
factors 
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Figure 26: Working model for the function of AICD regulated transcription
When membrane-bound, APP binds to the phosphotyrosine-binding domain 2 (PTB2) of its adaptor protein Fe65 
via its conserved NPTY domain at the C-terminus. Cleavage by α-, β- and γ-secretase takes place and the 
AICD/Fe65 complex is released into the cytoplasm. It translocates to the nucleus where Fe65 binds to the histone 
acetyltransferase Tip60 and transcription of genes is initiated.
factors resulted in transcriptional activation in cell lines, when co-transfected with the APP adaptor 
protein Fe65 and the histone acetyltransferase Tip60. Although the exact mechanism is not fully 
understood yet, the experiments of Cao et al. (2001 and 2004) suggest the following mechanism (Fig. 
26):
The AICD acts outside the nucleus as a membrane-tethered recruiting device for Fe65, comparable with 
the Notch CSL. Fe65 binds via its PTB (phosphotyrosine-binding) domain to a conserved NPTY motif 
in the C-terminus of the AICD and stabilizes it. The AICD needs to be membrane-bound to be able to 
bind Fe65. Cleavage by γ-secretase releases the AICD-Fe65 complex, which then translocates to the 
nucleus where Fe65 binds to Tip60 and initiates transcription. According to their sequence similarities, 
it is not surprising that APLP1 and APLP2 also release an intracellular domain after γ-secretase
cleavage. The APP-like intracellular domains 1 and 2 (ALICD1 and ALICD2) have also been shown to 
modulate gene transcription by forming a complex with Fe65 and Tip60 (Scheinfeld et al., 2002).
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So far, several target genes of AICD transcriptional regulation have been identified. Most of them are 
linked to APP turnover itself, such as APP, β-secretase and Tip60 (von Rotz et al., 2004). However, 
KAI1, another target gene, has no link to APP or Alzheimer′s disease (Baek et al., 2002). Recently, the
amyloid β degrading enzyme neprilysin has been identified as a target gene (Pardossi-Piquard et al., 
2005). Interestingly, its transcriptional regulation is not only controlled by the presence of the APP 
intracellular domain but also by the intracellular domains of APLP1 and APLP2. The authors could 
demonstrate that in the absence of app and aplp2 the decrease of neprilysin transcription was much 
stronger than in the absence of either gene alone. This favours a synergistic effect of both intracellular 
domains and argues for a partly redundant function of both proteins.
While most of the studies on AICD have been performed with AICD overexpressing cell lines, very 
recently, Kimberly et al. (2005) were able to detect endogenous AICD in primary neuronal cultures. 
Neurons are known to express high amounts of APP which enabled the authors to detect the labile 
intracellular fragment and to demonstrate that it undergoes a temporally restricted upregulation. The 
highest levels of AICD in the neurons were found after they had been in culture for 5 to 7 days. During 
this peak of AICD generation a sub-fraction was detected in the nucleus, suggesting its contribution in 
specific transcriptional events. The levels of the fragment decreased rapidly thereafter because of
phosphorylation of APP C-terminal fragments (CTFs) by C-Jun N-terminal kinase 3 (JNK3). The
phosphorylation prevents binding of AICD and Fe65 and results in AICD degradation. The short time 
period in which the AICD levels are upregulated coincide with the onset of synapse formation, leading 
the authors to suggest a role for AICD in synaptogenesis. Clearly, our results are in agreement with this 
hypothesis and transcriptional activation by AICD may provide a mechanism by which vglut2
transcription could be regulated. Additional support comes from the observation that treatment of wild-
type neurons with a γ-secretase inhibitor resulted in the downregulation of vglut2 transcription while 
another synaptic marker, synaptophysin, was not affected. The treatment of the neurons after 6 days in
culture for a time period of 6 days revealed a consistent downregulation of vglut2 transcription, while 
the treatment after 11 DIV showed more variations. This effect might be explained by the reported
upregulation of AICD in primary neurons after 5-7 days in culture. In addition, the time period of 
inhibition could be crucial as well. A treatment with γ-secretase inhibitor for 6 days might result in a 
substantial decrease of AICD levels and AICD mediated transcription. However, treatment for 24 hours 
might not be long enough to sufficiently decrease AICD levels in order to detect a similar effect on 
transcription.
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To further support a direct link between APP and VGLUT2 expression we are currently attempting to 
express AICD in ES cells lacking app and aplp2.
In addition to the effects obtained in the absence of APP and APLP2 we investigated whether vglut2
transcription levels are increased in the presence of additional APP. As has been described (Bibel et al., 
2004) APP is expressed already in neural progenitors in our system and its levels increase during the 
course of differentiation. By making use of neurons derived from ES cells expressing human APP 
driven by the endogenous tau promoter, we studied vglut2 transcription after 5-6 days in vitro. This 
represents the time point when VGLUT2 protein starts to be clearly detectable and APP did not yet 
reach a stable expression level. These time points happen to coincide with those time points Kimberly 
et al. (2005) reported the highest amount of AICD present in neurons. Although we were able to 
observe an increase of vglut2 transcription after 6 DIV we were not able to detect significantly 
increased amounts of total APP protein in the genetically modified neurons. Therefore we are not able 
to unambiguously link the observed effect on vglut2 transcription to the additional presence of human 
APP. We can only speculate according to the findings of Kimberly et al. that a small additional amount 
of APP at the time point of highest AICD generation could result in a significant change of 
transcription. 
4.4 Synaptic changes in mice lacking app and aplp2
The likelihood that both APP and APLP2 may be involved in synaptic function, possibly in a partly 
redundant fashion, was supported by two recent reports illustrating interesting structural changes in 
synapses of mice deficient in app and aplp2 (Wang et al., 2005; Yang et al., 2005). Although the 
synaptic architecture in these animals had already been examined to some extent by Heber et al. (2000) 
and no apparent differences in synapse density or ultrastructure were reported, the recent studies did 
provide evidence for reduced numbers of synaptic vesicles and reduced size and number of active zones 
at synapses of neuromuscular junctions and submandibular ganglia. The structural abnormalities led to 
functional impairments in synaptic transmission. In addition, the development of neuromuscular 
junctions appears to be disrupted in the double knock-out animals. Reduced levels of presynaptic
markers such 
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markers such as synaptophysin and synapsin were observed, as well as increased sprouting of nerve 
terminals (Wang et al., 2005). The latter observations are consistently found in animals with retarded 
development of their neuromuscular junctions. In view of the possible role of APP as a kinesin-1 cargo 
receptor (see Introduction, Kamal et al., 2000, 2001), these findings suggest that the lack of APP may 
disturb proper axonal trafficking, resulting in fewer synaptic vesicles present at the neuromuscular 
endplate. However, Wang et al. (2005), directly addressed this question in the double knock-out 
animals but failed to obtain any evidence for alterations of axonal transport. The axonal structures 
looked normal and did not show signs of swellings (so called “axonal clogging”), caused by organelle 
accumulation, as has been demonstrated to occur in cells with disrupted transport mechanisms 
(Gunawardena et al., 2001). 
Our observations that the absence of app and aplp2 results in changes of synapse maturation and 
function of glutamatergic synapses is in general agreement with the findings of Wang et al. (2005) and 
Yang et al. (2005), even though their observations were largely based on a different methodology, 
involving for the most part immunocytochemical and electrophysiological methods. 
Taken together, these two sets of observations suggest that in the combined absence of APP and 
APLP2, the development of both CNS glutamatergic and PNS cholinergic synapses may be retarded, 
perhaps as a result of delayed transcription of the corresponding target genes. In future experiments it 
will be interesting to examine the generality of this hypothesis linking genes of the APP family and 
synaptic function. This work may shed light not only on the physiological function of the APP-related 
genes, but also on the role of APP in pathological situations. It is now widely thought that besides Aβ
plaques and neurofibrillary tangles, synaptic dysfunctions may be an early function-related event in 
AD, long before Aβ plaque formation can be detected (Selkoe et al., 2002). The findings of the present 
study might provide insight into the mechanisms that mediate synaptic changes in Alzheimer′s disease. 
At least for some cases of early familiar Alzheimer′s disease (FAD) a link between mutations in
presenilin-1 and AICD generation has been demonstrated. Most of these mutations result in increased 
production of Aβ whereas the AICD generation is surprisingly decreased or even suppressed (Chen et 
al., 2002; Möhlmann et al., 2002). Thus, synaptic dysfunction in AD might be mediated by long-term 
alterations in AICD related transcription of the corresponding genes.
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